Micronized Bromocriptine Tablets for Consistent Rapid Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bromocriptine mesylate formulations for treating type 2 diabetes face challenges in achieving consistent and rapid drug release, leading to variability in efficacy and increased side effects due to inconsistent particle size distribution and settling of ingredients during manufacturing.
Innovation Solution
Manufacturing bromocriptine mesylate tablets using micronized bromocriptine mesylate with controlled particle size (Dv90 < 20 μm) and employing direct transfer of the blended mixture to the tablet press to ensure uniform distribution and consistent drug release, as well as incorporating excipients like citric acid and colloidal silicon dioxide to enhance stability and absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional bromocriptine mesylate formulations are used, then manufacturing is simpler, but drug release is inconsistent and side effects increase
Solution Approach 1:
The patent applies preliminary action by micronizing bromocriptine mesylate before tablet formulation. The active ingredient is ground to a fine powder with controlled particle size distribution (Dv90 < 20 μm) in advance, ensuring uniform distribution in the final tablet and consistent drug release, while avoiding the need for complex manufacturing processes
2Manufacturing precision
If particle size is not controlled, then manufacturing is easier, but drug content uniformity varies
Solution Approach 1:
The patent applies parameter changes by controlling the particle size parameter of bromocriptine mesylate. The active ingredient is micronized to achieve a specific particle size distribution (Dv90 < 20 μm), which fundamentally changes the physical parameter to ensure uniform distribution and consistent drug content in tablets, simplifying the manufacturing process
3Speed
If rapid drug release is achieved, then glycemic control improves, but side effects increase due to uncontrolled release
Solution Approach 1:
The patent applies local quality by creating different release characteristics through controlled particle size distribution. The micronized bromocriptine mesylate (Dv90 < 20 μm) provides rapid and consistent drug release throughout the dosage form, ensuring therapeutic effect while maintaining safety through uniform pharmacokinetics, rather than uncontrolled release
4Stability of the object's composition
If ingredients are allowed to settle during manufacturing, then processing is simpler, but tablet uniformity deteriorates
Solution Approach 1:
The patent applies preliminary action by micronizing the active ingredient before formulation, which prevents settling during manufacturing. The fine particle size (Dv90 < 20 μm) ensures uniform distribution and suspension stability, maintaining tablet composition uniformity without requiring complex anti-settling measures or specialized manufacturing equipment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method ensures a rapid and complete drug release profile, with at least 90% of bromocriptine mesylate released within 30 minutes, improving glycemic control and reducing side effects by maintaining consistent dosing and pharmacokinetic profiles.
Implementation Method 1
achieved through processes like jet milling
Implementation Method 2
The development of micronized bromocriptine mesylate tablets with a controlled particle size distribution
Data Source
AI summary
The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.